Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2-breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT04460911
What this trial is testing

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.

Who this might be right for
Breast Cancer
Pfizer 317
Testing effectiveness (Phase 2)UnknownNCT05806047
What this trial is testing

Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy

Who this might be right for
Hormone Receptor-positive Advanced Breast Cancer
Fudan University 23
Not applicableStudy completedNCT06040593
What this trial is testing

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer

Who this might be right for
Hormone-receptor-positive Breast CancerHER2-low Breast CancerHER2-negative Breast Cancer
Daiichi Sankyo 927
Testing effectiveness (Phase 2)UnknownNCT02214004
What this trial is testing

Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women

Who this might be right for
Breast Cancer
Gangnam Severance Hospital 132
Testing effectiveness (Phase 2)Looking for participantsNCT07395336
What this trial is testing

Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)

Who this might be right for
Breast Cancer
European Institute of Oncology 26
Testing effectiveness (Phase 2)UnknownNCT05322720
What this trial is testing

HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy

Who this might be right for
Solid Tumor, Adult
Taizhou EOC Pharma Co., Ltd. 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT06394661
What this trial is testing

Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Henan Cancer Hospital 109
Testing effectiveness (Phase 2)Looking for participantsNCT04553770
What this trial is testing

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Who this might be right for
Early-stage Breast CancerHormone Receptor Positive Breast CarcinomaInvasive Breast Cancer+4 more
Jonsson Comprehensive Cancer Center 88
Testing effectiveness (Phase 2)UnknownNCT05512416
What this trial is testing

Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
The Affiliated Hospital of Qingdao University 35
Testing effectiveness (Phase 2)Study completedNCT03822468
What this trial is testing

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 376
Testing effectiveness (Phase 2)Looking for participantsNCT07180160
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Wenjin Yin 123
Testing effectiveness (Phase 2)Active Not RecruitingNCT05252988
What this trial is testing

Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib

Who this might be right for
Early-stage Breast CancerHER2 Positive Breast CancerHormone Receptor Positive
Spanish Breast Cancer Research Group 177
Testing effectiveness (Phase 2)UnknownNCT05808582
What this trial is testing

Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer

Who this might be right for
Hormone Receptor-positive Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 60
Not applicableStudy completedNCT06086340
What this trial is testing

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Who this might be right for
Breast Cancer
Pfizer 779
Testing effectiveness (Phase 2)Looking for participantsNCT04819243
What this trial is testing

PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study

Who this might be right for
Premenopausal HR+/HER2- Metastatic Breast Cancer
Samsung Medical Center 178
Testing effectiveness (Phase 2)UnknownNCT04034589
What this trial is testing

Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 46
Not applicableStudy completedNCT02536625
What this trial is testing

Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)

Who this might be right for
Breast Cancer
Centre Leon Berard 62
Testing effectiveness (Phase 2)Study completedNCT06465368
What this trial is testing

Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause

Who this might be right for
Breast Cancer
Pfizer 121
Very early researchEnded earlyNCT04102618
What this trial is testing

A Window-of-opportunity Study of Pelareorep in Early Breast Cancer

Who this might be right for
Breast Cancer
Oncolytics Biotech 26
Not applicableLooking for participantsNCT06830720
What this trial is testing

A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence

Who this might be right for
Breast Neoplasms
Novartis Pharmaceuticals 3,250
Next Page